Challenging the Notion of Survivorship

Challenging the Notion of Survivorship

Posted by  | Survivorship

“If you looked at me, you would have no idea I have cancer,” acknowledges Maikki Nekton, a 37-year-old social worker and self-described workaholic with piercing blue eyes and a smile that lights up her whole face. If you didn’t know Maikki, you’d be even more shocked to find out that she’s been given a loose(...)

Researchers Advance Role of Circulating Tumor DNA to Detect Early Melanoma Growth, Uncover Treatment Options

Posted by  | Research, treatment

Researchers at the Johns Hopkins Kimmel Cancer Center say they have added to evidence that measuring and monitoring tumor DNA that naturally circulates in the blood of melanoma patients can not only reliably help reveal the early stages of cancer growth and spread but also uncover new treatment options that tumor genetic analysis alone may(...)

A perspective on an immunotherapy clinical trial

Posted by  | Patient Stories

This blog post was written by Kristina Baum, who has melanoma and is participating in a clinical trial on immunotherapy at the Johns Hopkins Kimmel Cancer Center. For more information on Kristina's story, watch her interview with Denise Grady on the New York Times' Facebook page or follow her on Twitter at @kristinabaum. For the post,(...)

One-third of patients with metastatic melanoma treated with immunotherapy drug nivolumab survive five years

Posted by  | Research

At the 2016 American Association for Cancer Research annual meeting today, scientists presented their results of a follow-up study tracking the survival of metastatic melanoma patients who were treated with the immunotherapy drug nivolumab. The drug is currently approved by the U.S. Food and Drug Administration for advanced lung and kidney cancers and advanced melanomas.(...)

Melanoma drug FDA approved

Posted by  | treatment

This week, the FDA approved a new therapy called talimogene laherparepvec, which goes by the trade name, Imlygic, for the treatment of certain types of melanoma. Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at the Johns Hopkins Kimmel Cancer Center offered the following insights on the drug's approval: “This approval(...)

The True Value of Volunteering

Posted by  | Survivorship

***This post was written by Deb Stewart, R.N., who leads a group of Survivor Volunteers in the Johns Hopkins Breast Center. In honor of National Volunteers Week, Deb pays tribute to her volunteer group and describes the value of volunteering. Like the volunteers we saw give their help during the Boston bombings, Deb's volunteers provide(...)

Cancer News Review

Posted by  | Research

Cancer headlines this past month included two studies on colonoscopy, a screening tool for colon cancer.  The first study looks at the long-term benefits of colonoscopy and found that 50 percent of colon cancer cases were avoided by a single colonscopy.  In the Cancer News Review podcast, William Nelson, M.D., Ph.D., director of the Johns Hopkins Kimmel Cancer(...)